CONCORD, Ohio--(BUSINESS WIRE)--Ricerca Biosciences, an integrated preclinical contract research organization (CRO) providing services to the biopharmaceutical industry, announces its attendance and presentations at the 47th Annual Congress of the European Societies of Toxicology (EuroTox).
The August 28-31, 2011, meeting will be held at the Palais des Congrès in Paris, France. The Company will be located at booth #2 during the meeting.
Ricerca’s scientists will present their world-class expertise in the form of poster abstracts while at EuroTox.
“At Ricerca, we are constantly searching for new and innovative ways to serve client needs,” stated Ian Lennox, CEO of Ricerca. “We are pleased to have the opportunity to present at EuroTox.”
Ricerca abstracts include:
- “Feasibility of a four-week ambulatory intravenous infusion in the dog for preclinical safety assessment. Impact on toxicological and histopathological endpoints” by J.P. Briffaux
- “Monitoring of arterial blood pressure in the freely moving Göttingen minipig with minimally invasive methods. Pharmacological validation with isoprenaline” by S. Milano, Ph.D.
- “Telemetric assessment of respiratory function by thoracic impedance pneumography in the anesthetized beagle dog. Comparison with ambulatory standard methods and pharmacological validation with hypercapnia, morphine and buspirone” by S. Milano, Ph.D.
- “Intramuscular injection sites: is the quality of the diagnosis improved when more than one tissue section is examined?” by J.P. Briffaux
- “Investigative embryo-fetal development study in the Göttingen minipig with a known swine teratogen using mid-term caesarean sections” by J.P. Briffaux
Ricerca Biosciences provides a full range of preclinical services from early discovery medicinal chemistry, compound screening, profiling and lead optimization through full drug safety, metabolism and efficacy development support, as well as clinical supply and commercial API production capability.
About Ricerca Biosciences
Ricerca Biosciences, offers a comprehensive suite of discovery, preclinical and development services to support drug candidates from discovery through IND and NDA on a global scale. Capabilities include molecular through in vivo screening and profiling, medicinal chemistry, IND-enabling toxicology, API process chemistry and cGMP manufacturing of clinical and commercial API. At Ricerca, our scientific excellence and reliable, cost-effective strategies help accelerate your drug discovery programs via our U.S.-based facilities in Concord, Ohio, and Bothell, Washington, and our ISO 9001-certified facilities in Taipei, Taiwan, and Lyon, France. The Lyon facility also holds AAALAC certification.